Does mismatch negativity have utility for NMDA receptor drug development in depression?

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Ketamine's rapid antidepressant effects highlight the shift to glutamatergic targets for major depressive disorder (MDD).
• N-methyl-D-aspartate (NMDA) receptor antagonists offer therapeutic potential but face challenges due to off-target effects and clinical issues.
• Biomarkers are crucial for monitoring target engagement and guiding the development of novel MDD therapeutics.

Purpose of the Study:

• To explore the utility of mismatch negativity (MMN) as an electrophysiological biomarker for NMDAR antagonist drug development in MDD.
• To evaluate the MMN's flexibility and reliability in assessing target engagement for NMDA receptor antagonists.
• To identify distinctions in NMDA receptor antagonism mechanisms and their impact on MMN measurement.

Main Methods:

• Review of MMN's role as an electrophysiological signature linked to NMDA receptor activity.
• Analysis of findings from research involving three distinct NMDAR antagonists (AV-101, lanicemine, ketamine).
• Examination of different MMN study paradigms and their influence on understanding NMDAR antagonism.

Main Results:

• MMN is a validated electrophysiological signature for NMDA receptor activity, relevant to ketamine studies.
• Distinct NMDAR antagonists exhibit varying mechanisms, further clarified by MMN study paradigms.
• Current lack of standardized MMN methodology hinders its widespread adoption in drug discovery.

Conclusions:

• MMN holds potential as a biomarker for NMDAR antagonist development in MDD.
• Standardization of MMN methodology is essential for its reliable application in clinical trials and drug discovery.
• Further research is needed to optimize MMN protocols for consistent and accurate assessment of NMDA receptor engagement.